AnaCardio
Announced 30 Sept 2026$70.5M · Series B · Manufacturing · Sweden
AnaCardio AB is a privately held clinical stage biopharmaceutical company developing novel drugs to treat heart failure.
“Swedish biotech AnaCardio raises $70.9M to advance 'safer' heart failure drug Swedish biotech AnaCardio raises $70.9M to advance ‘safer’ heart failure drug Patrik Strömberg, AnaCardio CEO September 29, 2026 07:00 AM EDT Financing Startups Exclusive: Swedish biotech AnaCardio raises $70.9M for 'safer' heart drug Ayisha Sharma News Reporter AnaC”
15 more sources tracked. Read the full press release and reporter coverage.
Sign up to read →Investors: Novo Holdings, Helsinn, Pureos Bioventures, Sound Bioventures, Industrifonden, Flerie, LLD Nybohov Invest AB, Innovestor Life Science.